Discover a study that suggest efruxifermin may offer delayed therapeutic benefits for patients with MASH-related cirrhosis.

NASH becomes MASH as medical experts replace stigmatizing "non-alcoholic" liver disease terminology with dignity-focused ...

A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

Health experts warn about the silent rise of chronic liver disease, urging for immediate actions in detection and treatment ...

During the first meeting of the Global Think-tank on Steatotic Liver Disease, supported by the Barcelona Institute for Global ...

Some 17 million people across the US, UK, Germany, and France are living with the most aggressive form of fatty liver disease ...

A new American Diabetes Association consensus statement provides guidance on screening, diagnosing, and managing metabolic ...

During the first meeting of the Global Think-tank on Steatotic Liver Disease, supported by the Barcelona Institute for Global ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

FRIDAY, June 6, 2025 (HealthDay News) — A repurposed diabetes drug can be an effective tool against fatty liver disease, a ...